welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
-
Emerging Therapies for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=4qtcyz4U...
-
Tadalafil and Sildenafil for Duchenne Muscular DystrophyThis study, supported by Parent Project ...
-
Dystrophin-Deficient CardiomyopathyDystrophinopathies are a group of distin...
-
L-citrulline and Metformin in Duchenne’s Muscular DystrophyThe purpose of the study is to show that...
-
Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyThis study is a long-term study of atalu...
-
Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociati...Santhera Pharmaceuticals and Idorsia Ltd...
-
UT Researcher, With CureDuchenne Support, Launches Company to Treat DMD Using CRISPR/Cas9 TechnologyEric Olson, a molecular biologist, has s...
